First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma - Concepedia

Concepedia

Publication | Open Access

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

DOI Full Paper Access

23

Citations

14

References

2023

Year

Julius Strauss, Jean‐Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K. Pachynski, Theodore Stewart Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom,

Journal for ImmunoTherapy of Cancer

Abstract

M9241 plus avelumab was well tolerated at all DLs, including the dose-expansion part, with no new safety signals. However, the dose-expansion part did not meet the predefined efficacy criterion to proceed to stage 2.

References

	Year	Citations

Page 1